Icon	Function
💬	A pop-up explanation appears when you mouse-over the text beside this icon. Also, an explanation window appears when you click this icon.
	The links beside this icon are links to external sites.
	Clicking this icon sorts the table by the item with this icon (Numerical or alphabetical order). Each click toggles between ascending and descending order.
	A text longer than 100 characters is fully displayed or collapsed.
	The contents of the displayed table are downloaded as a file named "table.csv".

DR info

Clinical trials : 35 / Drugs : 45 - (DrugBank : 11) / Drug target genes : 8 - Drug target pathways : 19

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)

Blood sample collection FOR ecfc isolation and characterization
   Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
      2023   -   NCT07358013   Italy
Blood sample collection FOR VWF measurements IN plasma
   Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
      2023   -   NCT07358013   Italy
Bortezomib
   Institute of Hematology& Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
      2020   Phase 4   ChiCTR2000035067   China
   Peking Union Medical College Hospital
      2018   Phase 2   NCT03700229   China
BT200
   Medical University of Vienna
      2020   Phase 2   EUCTR2020-003807-32-AT   Austria
Coagulation factor xiii
   NOVO NORDISK
      2008   -   EUCTR2006-003148-51-IT   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
Cyclophosphamide
   Institute of Hematology & Blood Diseases Hospital, China
      2017   Phase 4   NCT03384277   China
Daratumumab and corticosteroid treatment
   Institute of Hematology & Blood Diseases Hospital, China
      2023   Phase 4   NCT05849740   China
Desmopressin
   Pontificia Universidad Catolica de Chile
      2009   Phase 4   NCT01994330   Chile
Emicizumab
   Chugai Pharmaceutical Co., Ltd.
      2020   Phase 3   JPRN-jRCT2080225056   Japan
   University of Washington
      2022   Phase 2   NCT05345197   United States
Emicizumab injection
   GWT-TUD GmbH
      2021   Phase 2   NCT04188639   Austria;Germany
F13CD
   NOVO NORDISK
      2008   -   EUCTR2006-003148-51-IT   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
Fibrinogen plasma concentration, coagulation factor xiii activity
   Masaryk Hospital Krajská zdravotní a.s.
      2018   -   NCT03634215   Czechia
Fibrogammin
   Christian Haslinger
      2024   Phase 4   NCT06481995   Switzerland
Genetic testing OF VWF
   Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
      2023   -   NCT07358013   Italy
OBI-1
   Baxalta now part of Shire
      2014   -   NCT01968655   United States
      2010   Phase 2/Phase 3   NCT01178294   Canada;France;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States
   Baxter Innovations GmbH
      2012   -   EUCTR2011-000181-34-SE   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States
      2012   -   EUCTR2011-000181-34-HU   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States
      2012   -   EUCTR2011-000181-34-DE   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-000181-34-GB   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States
   INSPIRATION BIOPHARMACEUTICALS
      2012   -   EUCTR2011-000181-34-IT   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States
Obizur
   Baxalta now part of Shire
      2015   -   NCT02610127   United States
   Takeda
      2025   -   NCT06550882   South Korea
Obyoctocog alfa
   Baxter Innovations GmbH
      2012   -   EUCTR2011-000181-34-SE   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States
      2012   -   EUCTR2011-000181-34-HU   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States
      2012   -   EUCTR2011-000181-34-DE   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-000181-34-GB   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States
Octostim
   Abteilung für Herz-Thorax-Gefäß Anästhesie & Intensivmedizin (HTG)
      2006   Phase 4   EUCTR2005-004559-36-AT   Austria
Physiologische kochsalzlösung fresenius - infusionslösung
   Medizinische Universität Innsbruck / Univ.-Klinik für Allgemeine und Chirurgische Intensivmedizin
      2017   Phase 2   EUCTR2016-000789-53-AT   Austria
   Tirol Kliniken GmbH
      2017   Phase 2   EUCTR2017-003036-37-AT   Austria
Phytomenadione
   Region Skane
      2019   -   NCT03782025   Sweden
Prednisone
   Georgetown University
      2006   Phase 2/Phase 3   NCT00306670   United States
Prothrombin complex concentrate
   CSL Behring
      2005   Phase 3   NCT00168077   Austria;Germany;Hungary;Israel;Lithuania;Netherlands;Poland;Switzerland
Rituxan
   Georgetown University
      2006   Phase 2/Phase 3   NCT00306670   United States
Rituximab
   Institute of Hematology & Blood Diseases Hospital, China
      2017   Phase 4   NCT03384277   China
   Peking Union Medical College Hospital
      2018   Phase 2   NCT03700229   China
RO5534262 emicizumab
   GWT-TUD GmbH
      2021   Phase 2   EUCTR2019-004430-42-DE   Austria;Germany
      2021   Phase 2   EUCTR2019-004430-42-AT   Austria;Germany
Saline solution
   Tirol Kiniken GmbH
      2018   Phase 2   NCT03613584   Austria
Sodium chloride
   Medizinische Universität Innsbruck / Univ.-Klinik für Allgemeine und Chirurgische Intensivmedizin
      2017   Phase 2   EUCTR2016-000789-53-AT   Austria
   Tirol Kliniken GmbH
      2017   Phase 2   EUCTR2017-003036-37-AT   Austria
Steroid
   Institute of Hematology & Blood Diseases Hospital, China
      2017   Phase 4   NCT03384277   China
Susoctocog alfa
   Takeda
      2024   -   NCT06461533   Japan
TAK-672
   Koumura Emiko
      2021   Phase 2-3   JPRN-jRCT2051200066   -
   Takeda
      2021   Phase 2/Phase 3   NCT04580407   Japan
VON willebrand factor
   Medizinische Universität Innsbruck / Univ.-Klinik für Allgemeine und Chirurgische Intensivmedizin
      2017   Phase 2   EUCTR2016-000789-53-AT   Austria
   Tirol Kiniken GmbH
      2018   Phase 2   NCT03613584   Austria
   Tirol Kliniken GmbH
      2017   Phase 2   EUCTR2017-003036-37-AT   Austria
VON willebrand faktor
   Medizinische Universität Innsbruck / Univ.-Klinik für Allgemeine und Chirurgische Intensivmedizin
      2017   Phase 2   EUCTR2016-000789-53-AT   Austria
   Tirol Kliniken GmbH
      2017   Phase 2   EUCTR2017-003036-37-AT   Austria
Willfact
   Medizinische Universität Innsbruck / Univ.-Klinik für Allgemeine und Chirurgische Intensivmedizin
      2017   Phase 2   EUCTR2016-000789-53-AT   Austria
   Tirol Kliniken GmbH
      2017   Phase 2   EUCTR2017-003036-37-AT   Austria